Drugs / H5N1 antigen combined with MF59 adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04669691 | Dec 2020 → Apr 2022 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5N1 antigen combined with MF59 adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04669691 ↗ |
| Modality | Vaccine | “Monovalent H5N1 Pandemic Influenza Vaccine” NCT04669691 ↗ |
| Route | Intramuscular | “Two consecutive intramuscular (IM) administrations (Day 1 and Day 22)” NCT04669691 ↗ |